Skip Navigation
Department of Health and Human Services www.hhs.gov
 
Slide Tray
0 slides

Return to Slide Library

Slides

Add Presentation to Slide Tray Presentation:

First- and Second-Generation Antipsychotics for Children and Young Adults

Slide: 39 of 43

Conclusions About the Benefits and Adverse Effects of Antipsychotics (1 of 2)

  • Evidence about the use of antipsychotics in children and adolescents is inadequate to support strong conclusions about their comparative effectiveness.
  • Moderate-strength evidence indicates that second-generation antipsychotics (SGAs) as a class improve clinical global impressions in bipolar disorder, and low-strength evidence supports benefits for treating mania.
  • Moderate-strength evidence shows that SGAs as a class improve both clinical global impressions and positive and negative symptoms of schizophrenia.
  • Moderate-strength evidence shows that risperidone is effective for attention deficit hyperactivity disorder and disruptive behavior disorders, and that risperidone and ziprasidone can reduce tics in Tourette’s syndrome.
  • Limited evidence suggests that SGAs are more effective than first-generation antipsychotics for improving some autistic symptoms of pervasive developmental disorders.